Sacituzumab govitecan-hziy: Detailed Review of its Transformative R&D Success

Sacituzumab govitecan-hziy's R&D Progress

Sacituzumab govitecan-hziy is a drug classified as a monoclonal antibody and an antibody drug conjugate (ADC). It targets TOP1 and Trop-2, making it suitable for various therapeutic areas such as neoplasms, digestive system disorders, endocrinology and metabolic disease, mouth and tooth diseases, respiratory diseases, urogenital diseases, and skin and musculoskeletal diseases.

The drug has been approved for multiple indications, including hormone receptor-positive HER2-negative breast cancer, breast cancer, transitional cell carcinoma, metastatic breast cancer, liver function failure, etc.

The drug was developed by Immunomedics, Inc., and it has received approvals in the global markets. Its first approval was granted in the United States in April 2020. The drug has undergone various regulatory processes, including priority review, accelerated approval, fast-track designation, orphan drug status, and breakthrough therapy designation.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Mechanism of Action for Sacituzumab govitecan-hziy: TOP1 inhibitors and Trop-2 inhibitors

TOP1 inhibitors are a type of drug that specifically target and inhibit the activity of the enzyme topoisomerase I (TOP1). Topoisomerases are enzymes involved in the regulation of DNA topology, which is essential for DNA replication, transcription, and repair. TOP1 inhibitors work by binding to the active site of the TOP1 enzyme, preventing it from properly functioning. This inhibition leads to the accumulation of DNA strand breaks and ultimately disrupts DNA replication and transcription processes in cancer cells. Therefore, TOP1 inhibitors are primarily used in cancer treatment to inhibit the growth and proliferation of cancer cells.

Trop-2 inhibitors, on the other hand, target the Trop-2 protein. Trop-2, also known as tumor-associated calcium signal transducer 2, is a cell surface glycoprotein that is overexpressed in various types of cancer cells. It plays a role in promoting cell proliferation, migration, and survival. Trop-2 inhibitors are designed to specifically bind to Trop-2 and block its function. By inhibiting Trop-2, these inhibitors can interfere with the signaling pathways involved in cancer cell growth and metastasis. Trop-2 inhibitors have shown potential as targeted therapies for different types of cancers, including breast, lung, and pancreatic cancer.

In summary, TOP1 inhibitors target the enzyme topoisomerase I to disrupt DNA replication and transcription in cancer cells, while Trop-2 inhibitors specifically inhibit the Trop-2 protein to interfere with cancer cell growth and metastasis. Both types of inhibitors are being explored as potential treatments for various types of cancer.

Drug Target R&D Trends for Sacituzumab govitecan-hziy

According to Patsnap Synapse, as of 13 Sep 2023, there are a total of 8 TOP1 + Trop-2 drugs worldwide, from 24 organizations, covering 38 indications, and conducting 120 clinical trials.

The analysis of the current competitive landscape of target TOP1 + Trop-2 reveals that multiple companies are actively involved in the development of drugs targeting this target. Gilead Sciences, Inc., Everest Medicines II (HK) Limited, and Daiichi Sankyo Co., Ltd. are among the companies with the highest stage of development. These companies have made significant progress in obtaining regulatory approvals and advancing their drugs through various stages of development. The indications for which drugs have been approved under this target cover a wide range of cancers, indicating the potential for addressing multiple unmet medical needs. The presence of different drug types, such as antibody drug conjugate (ADC) and monoclonal antibody, suggests a diverse approach to targeting TOP1 + Trop-2. The development of drugs targeting this target is not limited to specific countries or locations, with significant progress observed in China, the United States, and various European countries. Overall, the future development of target TOP1 + Trop-2 holds promise for addressing critical medical needs in the field of oncology.

👇Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target

Conclusion

In summary, Sacituzumab govitecan-hziy is a monoclonal antibody and antibody drug conjugate that targets TOP1 and Trop-2. It has been approved for multiple indications, primarily in the field of oncology, including breast cancer, lung cancer, bladder cancer, ovarian cancer, and various other solid tumors. The drug has shown promising results and has received regulatory designations that expedite its development and approval process. Its originator organization is Immunomedics, Inc., and it has obtained approvals in the global markets.